We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In Abbott Laboratories v. Sandoz, Inc., the Federal Circuit, in an unannounced and possibly rule-contravening partial-en banc decision, adopted a bright-line rule for determining infringement of a product-by-process patent claim
This past September, a three-judge panel of the Federal Circuit rendered a decision that may have rippling effects on how alleged infringers defend against allegations of willful infringement
